# US 2001/0044123 A1 · Assays for diagnosis of thrombophilic disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0044123 A1
- Document ID: US20010044123A1
- Status: Published application
- Kind: A1
- Application number: 09/796,023
- Filed: 2001-02-28
- Published: 2001-11-22
- Earliest claimed: 1997-07-11
- Assignees: Mount Sinai School of Medicine of the City University of New York
- Inventors: Jacob H. Rand
- Web page: https://patentgrep.com/patent/US20010044123A1

## CPC

- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 2333/4718: Lipocortins
- G01N 2405/04: Phospholipids, i.e. phosphoglycerides
- Y10S 435/81: Packaged device or kit
- Y10S 435/968: High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
- Y10S 436/801: Electron dense compounds, e.g. ferritin
- Y10S 436/804: Radioisotope, e.g. radioimmunoassay
- Y10S 436/806: Electrical property or magnetic property
- Y10S 436/811: Test for named disease, body condition or organ function
- Y10S 436/812: Infectious mononucleosis
- Y10T 436/105831: Protein or peptide standard or control [e.g., hemoglobin, etc.]
- Y10T 436/107497: Preparation composition [e.g., lysing or precipitation, etc.]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding of an anticoagulant protein, annexin, preferably annexin-V, to phospholipids by antiphospholipid (aPL) antibodies in a patient blood sample.

## Claims

### Claim 1

A method of diagnosing and/or monitoring a thrombophilic disease in a patient comprising
a. incubating a phospholipid substrate with a test blood specimen from the patient in the presence of a known amount of an annexin for a time sufficient to allow the annexin to bind to the phospholipid substrate,
b. removing unbound test specimen and annexin from the phospholipid substrate,
c. measuring the amount of annexin bound to the phospholipid substrate in the presence of the test specimen, and
d. comparing the amount of annexin bound in the presence of the test specimen to the same known amount of annexin bound to a phospholipid substrate in the presence of a control blood specimen, wherein a lower amount of annexin bound to the phospholipid substrate in the presence of the test specimen compared with the control specimen indicates the presence of thrombophilic disease in the individual.

### Claim 2

A method of diagnosing and/or monitoring a thrombophilic disease in a patient comprising
a. incubating a phospholipid substrate with a test blood specimen from the patient in the presence of a known amount of an annexin for a time sufficient to allow the annexin to bind to the phospholipid substrate,
b. removing unbound test specimen and annexin from the phospholipid substrate,
c. measuring the amount of unbound annexin from step b, and
d. comparing the amount of unbound annexin from step b to an amount of unbound annexin in a sample of annexin bound to a phospholipid substrate in the presence of a control blood specimen, wherein a higher amount of unbound annexin in the presence of the test specimen compared to the amount of unbound annexin in the presence of the control specimen indicates the presence of thrombophilic disease.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2 wherein the patient has or is suspected of having the antiphospholipid syndrome.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2 wherein the annexin is annexin-V.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2 wherein the test specimen and control specimen comprise anticoagulated plasma.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2 wherein the test specimen and control specimen comprise isolated IgG.

### Claim 7 (depends on 6)

The method of claim 6 wherein the incubation is carried out in the presence of a cofactor that enhances antiphospholipid antibody binding to the phospholipid substrate.

### Claim 8 (depends on 7)

The method of claim 7 wherein the cofactor is β2-glycoprotein I.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2 wherein the phospholipid substrate is selected from among cultured trophoblasts, endothelial cells, other cells and cultured cell lines having surface anionic phospholipids, platelets, phospholipid coated silicon wafers, phospholipid coated microtiter plates, phospholipid coated beads, phospholipid suspensions and coagulation test reagents comprising phospholipids.

### Claim 10 (depends on 9)

The method of claim 9 wherein the coagulation test reagent is selected from among partial thromboplastin time reagent and prothrombin reagent.

### Claim 11 (depends on 9)

The method of claim 9 wherein the phospholipid substrate comprises a phospholipid selected from among phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, cardiolipin, phosphatidic acid and combinations thereof.

### Claim 12 (depends on 9)

The method of claim 9 wherein the phospholipid substrate is a phospholipid coated microtiter plate or phospholipid coated beads.

### Claim 13 (depends on 9)

The method of claim 9 wherein the phospholipid substrate is platelets.

### Claim 14 (depends on 9)

The method of claim 9 wherein the phospholipid substrate is partial thromboplastin time reagent.

### Claim 15 (depends on 9)

The method of claim 9 wherein the phospholipid substrate is prothrombin reagent.

### Claim 16 (depends on 1, 2)

The method of claim 1 or 2 wherein the annexin comprises a detectable label.

### Claim 17 (depends on 16)

The method of claim 16 wherein the detectable label is selected from among biotin, a fluorochrome, a radioisotope, a chemiluminescent label and a chromophore.

### Claim 18 (depends on 17)

The method of claim 17 wherein the fluorochrome is fluorescein isothiocyanate.

### Claim 19 (depends on 1)

The method of claim 1 further comprising removing the bound annexin form the phospholipid substrate for measurement.

### Claim 20 (depends on 19)

The method of claim 19 wherein the annexin is removed by desorbing with a calcium chelating agent.

### Claim 21 (depends on 20)

The method of claim 20 wherein the calcium chelating agent is EDTA or EGTA.

### Claim 22 (depends on 1)

The method of claim 1 wherein bound annexin is measured by an ELISA, streptavidin binding, fluorescence or chemiluminescence.

### Claim 23 (depends on 20)

The method of claim 20 wherein desorbed annexin is measured by an ELISA, streptavidin binding, fluorescence or chemiluminescence

### Claim 24

A method of diagnosing and/or monitoring thrombophilic disease in a patient comprising
a. incubating in duplicate a phospholipid dependent coagulation test reagent with a sample of anticoagulated patient plasma,
b. calcifying the plasma in one of the duplicate sample of step a in the presence of a standardized amount of annexin and calcifying the plasma in the other sample in the absence of annexin, and
c. monitoring the time until clot formation occurs in each sample, wherein a reduced anticoagulant effect in the presence of annexin indicates thrombophilic disease in the patient.

### Claim 25 (depends on 24)

The method of claim 24 wherein the phospholipid dependent coagulation test phospholipid substrate is selected from among partial thromboplastin time reagent and prothrombin reagent.

### Claim 26 (depends on 24)

The method of claim 24 wherein the patient has the antiphospholipid antibody syndrome.

### Claim 27 (depends on 24)

The method of claim 24 wherein the annexin is annexin-V.

### Claim 28 (depends on 24)

The method of claim 24 wherein the plasma is citrated.

### Claim 29

A method of diagnosing and/or monitoring thrombophilic disease in a patient compising
a. incubating in duplicate a phospholipid dependent coagulation test reagent with a sample of anticoagulated patient plasma or isolated patient IgG,
b. removing unbound plasma or IgG from the coagulation test reagent,
c. incubating the duplicate samples of step b with a sample of control plasma,
d. calcifying the control plasma in one of the duplicate samples of step c in the presence of a standardized amount of annexin and calcifying the control plasma in the other sample in the absence of annexin, and
e. monitoring the time until clot formation occurs in each sample, wherein a reduced anticoagulant effect in the presence of annexin indicates thrombophilic disease in the patient.

### Claim 30 (depends on 25)

The method of claim 25 wherein the phospholipid dependent coagulation test phospholipid substrate is selected from among partial thromboplastin time reagent and prothrombin reagent.

### Claim 31 (depends on 26)

The method of claim 26 wherein the patient has the antiphospholipid antibody syndrome.

### Claim 32 (depends on 27)

The method of claim 27 wherein the annexin is annexin-V.

### Claim 33 (depends on 28)

The method of claim 28 wherein the plasma is citrated.

### Claim 34 (depends on 28)

The method of claim 28 wherein the control plasma is pooled normal plasma.
